The nationwide experiment will initially include around 100,000 volunteers.
Drug efficacy and resistance mechanisms shine a light on how drugs enter cells, which could facilitate the development of new sleeping-sickness treatments.
June 1, 2012|
WIKIMEDIA COMMONS, ALAN R. WALKER
S. Alsford et al., “High-throughput decoding of antitrypanosomal drug efficacy and resistance,” Nature, 482:232-36, 2012.
Trypanosoma brucei, the single-cell protozoan that causes the tropical disease sleeping sickness, is becoming increasingly resistant to the few drug treatments available. Using RNA interference (RNAi), David Horn of the London School of Hygiene and Tropical Medicine and colleagues identified 55 genes that contribute to drug susceptibility and resistance.
Horn used a library of plasmids to create around 750,000 T. brucei clones, each with one of the bug’s 7,500 or so genes knocked down using RNAi. He then treated the pool with five different sleeping sickness drugs, selecting for those clones that gained resistance by losing a gene. Using next-generation sequencing, the team identified 55 susceptibility-related genes in the survivors, marked by the RNAi sequences that had silenced them.
Horn and colleagues also gained insights into how these genes, when knocked down, might work. Out of 8 genes whose disabling conferred resistance to the first-line drug suramin, one encoded a previously unidentified cell-surface receptor, ISG75. When ISG75 was knocked down, the drug could not bind to the pathogen’s cell membrane—evidence of how suramin enters and kills cells through endocytosis.
The paper is important “mainly because we [now] understand better how these drugs work,” said microbiologist Christine Clayton of the University of Heidelberg, which could help researchers design new drugs that bypass the resistance mechanism.